PCDS consensus statement: A strategy for managing the supply shortage of the GLP-1 RAs Ozempic and Trulicity

In recent days, the PCDS has been made aware of GLP-1 receptor agonist shortages in the UK. Due to increased global use, manufacturers are currently unable to produce enough to meet demand. This is not a consequence of any safety or quality-related concern. While they are trying to address this, stock remains very low. Therefore, the PCDS proposes a strategy to ensure that, where supply is limited, people with diabetes can be safely switched to alternative agents within the GLP-1 RA class. Click here to access the statement.